Logo image of ALCJ.PA

CROSSJECT (ALCJ.PA) Stock Fundamental Analysis

Europe - EPA:ALCJ - FR0011716265 - Common Stock

2.42 EUR
-0.13 (-5.1%)
Last: 10/31/2025, 7:00:00 PM
Fundamental Rating

1

Overall ALCJ gets a fundamental rating of 1 out of 10. We evaluated ALCJ against 62 industry peers in the Health Care Equipment & Supplies industry. ALCJ has a bad profitability rating. Also its financial health evaluation is rather negative. ALCJ has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALCJ had negative earnings in the past year.
ALCJ had a negative operating cash flow in the past year.
In the past 5 years ALCJ always reported negative net income.
In the past 5 years ALCJ always reported negative operating cash flow.
ALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

With a Return On Assets value of -40.53%, ALCJ is not doing good in the industry: 85.48% of the companies in the same industry are doing better.
ALCJ's Return On Equity of -470.75% is on the low side compared to the rest of the industry. ALCJ is outperformed by 90.32% of its industry peers.
Industry RankSector Rank
ROA -40.53%
ROE -470.75%
ROIC N/A
ROA(3y)-34.88%
ROA(5y)-33.65%
ROE(3y)-354.28%
ROE(5y)-361.76%
ROIC(3y)N/A
ROIC(5y)N/A
ALCJ.PA Yearly ROA, ROE, ROICALCJ.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALCJ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCJ.PA Yearly Profit, Operating, Gross MarginsALCJ.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

ALCJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALCJ has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALCJ has more shares outstanding
Compared to 1 year ago, ALCJ has a worse debt to assets ratio.
ALCJ.PA Yearly Shares OutstandingALCJ.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ALCJ.PA Yearly Total Debt VS Total AssetsALCJ.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of 0.58, we must say that ALCJ is in the distress zone and has some risk of bankruptcy.
ALCJ has a Altman-Z score of 0.58. This is in the lower half of the industry: ALCJ underperforms 75.81% of its industry peers.
A Debt/Equity ratio of 2.97 is on the high side and indicates that ALCJ has dependencies on debt financing.
The Debt to Equity ratio of ALCJ (2.97) is worse than 90.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.97
Debt/FCF N/A
Altman-Z 0.58
ROIC/WACCN/A
WACC7.63%
ALCJ.PA Yearly LT Debt VS Equity VS FCFALCJ.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 0.83 indicates that ALCJ may have some problems paying its short term obligations.
With a Current ratio value of 0.83, ALCJ is not doing good in the industry: 87.10% of the companies in the same industry are doing better.
A Quick Ratio of 0.54 indicates that ALCJ may have some problems paying its short term obligations.
ALCJ has a worse Quick ratio (0.54) than 87.10% of its industry peers.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.54
ALCJ.PA Yearly Current Assets VS Current LiabilitesALCJ.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

ALCJ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.99%.
ALCJ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-23.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.65%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 56.27% on average over the next years. This is a very strong growth
ALCJ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 94.14% yearly.
EPS Next Y125.14%
EPS Next 2Y82.01%
EPS Next 3Y56.27%
EPS Next 5YN/A
Revenue Next Year146.18%
Revenue Next 2Y110.31%
Revenue Next 3Y94.14%
Revenue Next 5YN/A

3.3 Evolution

ALCJ.PA Yearly Revenue VS EstimatesALCJ.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
ALCJ.PA Yearly EPS VS EstimatesALCJ.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ALCJ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 37.13, the valuation of ALCJ can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as ALCJ.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.52, ALCJ is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 37.13
ALCJ.PA Price Earnings VS Forward Price EarningsALCJ.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCJ.PA Per share dataALCJ.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALCJ's earnings are expected to grow with 56.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y82.01%
EPS Next 3Y56.27%

More info and screens

0

5. Dividend

5.1 Amount

ALCJ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CROSSJECT

EPA:ALCJ (10/31/2025, 7:00:00 PM)

2.42

-0.13 (-5.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-24 2025-09-24
Earnings (Next)03-25 2026-03-25/amc
Inst Owners0.18%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap125.09M
Revenue(TTM)N/A
Net Income(TTM)-12795000
Analysts84.44
Price Target3.37 (39.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-61.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-39.81%
Revenue NY rev (3m)-39.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 37.13
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 46.02
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)0.07
Fwd EY2.69%
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.05
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.53%
ROE -470.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.88%
ROA(5y)-33.65%
ROE(3y)-354.28%
ROE(5y)-361.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.97
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.54
Altman-Z 0.58
F-Score3
WACC7.63%
ROIC/WACCN/A
Cap/Depr(3y)131.18%
Cap/Depr(5y)130.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.65%
EPS Next Y125.14%
EPS Next 2Y82.01%
EPS Next 3Y56.27%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year146.18%
Revenue Next 2Y110.31%
Revenue Next 3Y94.14%
Revenue Next 5YN/A
EBIT growth 1Y-9.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year219.31%
EBIT Next 3Y71.59%
EBIT Next 5YN/A
FCF growth 1Y8.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.35%
OCF growth 3YN/A
OCF growth 5YN/A

CROSSJECT / ALCJ.PA FAQ

What is the fundamental rating for ALCJ stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALCJ.PA.


What is the valuation status of CROSSJECT (ALCJ.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to CROSSJECT (ALCJ.PA). This can be considered as Overvalued.


What is the profitability of ALCJ stock?

CROSSJECT (ALCJ.PA) has a profitability rating of 0 / 10.


Can you provide the financial health for ALCJ stock?

The financial health rating of CROSSJECT (ALCJ.PA) is 0 / 10.